Can Noninvasive Tests Substitute Endoscopy for Diagnosis of Colonic Diseases?

Background and Aims: Fecal calprotectin was certified as a non-invasive hide tool for organic colonic ailments. The aim of this study search out evaluate fecal calprotectin and instigative indices as non-obtrusive markers for diagnosing and differentiating instigative bowel diseases (IBD) and colorectal malignancy (CRC) in comparison to irritable bowel condition (IBS) in a cohort of Egyptian cases.Methods: In this cross-sectional study, fecal calprotectin, neutrophil lymphocyte percentage (NLR), platelet lymphocyte ratio (PLR) and intrinsic inflammatory index (SII) were assessed in 40 IBD cases, 40 CRC patients, and 20 IBS victims.Results: Fecal calprotectin was significantly higher in IBD and CRC groups distinguished to IBS control group (P= 0.018 and 0.022 respectively), accompanying no significant difference 'tween IBD and CRC groups. PLR, NLR and SII showed no important differences middle from two points the 3 studied groups (P= 0.469, 0.101 and 0.84 respectively). At a stop value 113, polluted calprotectin had the ability to differentiate CRC subjects from IBS patients accompanying 75% sensitivity and 60% specificity, while At halt value of 116, polluted calprotectin had the ability to differentiate IBD victims from IBS patients accompanying 67.5% sensitivity and 65% specificity.Conclusion: Inflammatory indications tested in our study (PLR, NLR, SII) demonstrated no role for the differentiation betwixt IBD, CRC, and IBS. Fecal calprotectin should be secondhand with caution as a primary step for protect of colonic diseases as it cannot change IBD from CRC. It has only moderate sensitivity in differentiating IBD and CRC from IBS. Unfortunately, neither polluted calprotectin nor inflammatory indications can substitute endoscopy in the screening or diagnosis of IBD and CRC.

Please read full article -https://journalajarr.com/index.php/AJARR/article/view/449